Connect with us


The Covid-19 vaccine in Oxford may seem safe, but more research is needed


Results of trials with three different coronavirus vaccines released. All show positive results. Vaccines can produce an immune response that can be expected to protect people from infections. They all seem safe, even if they do research with more people to show that they are really safe and can prevent infection. The initial results of the Phase 1/2 trial, published in The Lancet, suggest a coronavirus vaccine developed by the University of Oxford and that AstraZeneca is safe and causes an immune response. However, the researchers stressed that more research is needed to find out whether the vaccine protects people against the virus. Phase 2 of the nomination for vaccine by Chinese company CanSino Biologics was also published in The Lancet and the results of Phase 1/2 of the vaccine testing by Pfizer and BioNTech were released on pre-printed paper. have yet to be reviewed. The Oxford vaccine triggered an antibody response within 28 days and a cell T response within 14 days, according to results released Monday. Neutralizing antibodies – so-called because they neutralize the virus – were detected in most participants after one shot, and in all after two. That’s good news, the researchers said. “The immune system has two ways to detect and attack pathogens: antibodies and T cell responses. The vaccine aims to cause both. So it can attack the virus when it circulates in the body, as well as attack infected cells,” the university said. Dr Andrew Pollard of Oxford, PhD in paediatrics, is the lead author of the study, he said. “We hope this will remind the immune system of the virus, so our vaccine will protect people for a long time. However, we need more research to confirm that the vaccine effectively protects against SARS-CoV-2 infection. Any long-term protection.” It is also unclear how Covid-19 would vaccinate elderly people at risk for serious illness. # Covid-19 #CNN #Notes.



to request, modification Contact us at Here or [email protected]